WALTHAM, Mass • 2023-11-29

BostonGene Wins Fierce Life Sciences Innovation Award for AI-Driven Clinical Trials Matching Algorithm

5 min to read

Award Recognizes BostonGene for Commitment to Innovation and the Profound Impact of AI-driven Solutions
WALTHAM, Mass – November 29, 2023 – BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, announced today that it has won the 2023 Fierce Life Sciences Innovation Award for its AI-driven clinical trials selection tool. The program, produced by Fierce Biotech and Fierce Pharma, recognizes innovations that exemplify effectiveness, technical innovation, competitive advantage, financial impact, and true innovation with the potential to transform the industry.

A panel of industry experts evaluated the submissions on various criteria and selected companies that demonstrate novel innovative technologies and services with the greatest potential to impact biotech and pharma companies.

“This year’s winners reflect the growing impact of technology on our industry – AI, machine learning, and data collection continues to be adopted across every aspect of the industry,” said Rebecca Willumson, SVP and Publisher of Fierce Biotech and Fierce Pharma. “We are so pleased to showcase innovative companies that are pushing boundaries and driving us forward. Congratulations to the 2023 class of winners.”

“We are elated to receive this 2023 Fierce Innovation Award, reinforcing the impact of our AI-driven technologies in improving patient outcomes and advancing research,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

BostonGene has developed a proprietary AI-driven clinical trials matching algorithm, seamlessly integrated into the BostonGene Tumor Portrait™ test, a comprehensive genomic profiling (CGP) solution for oncology patients.

The system utilizes a fully automated scoring algorithm that rapidly ranks the most relevant trials for each patient, incorporating AI-based expert-curated trial data extraction, trial results, as well as patient and molecular data. This algorithm relies on more than 80 dynamic parameters for personalized clinical trial recommendations.

BostonGene’s cell deconvolution tool, Kassandra™, was also named a finalist in the Fierce Innovation Awards, Data Analytics/Business Intelligence category for remarkable contributions to business intelligence through the application of data science, data management, and data analytics, all aimed at enhancing industry services.

Kassandra™ is a pioneering technology designed to precisely reconstruct the tumor microenvironment (TME). This innovative approach combines bulk RNA-seq with a unique machine learning-based platform trained on transcriptomes from over 25,000 bulk RNA-seq profiles. The utilization of this tool leads to an enhanced comprehension of underlying mechanisms governing cancer pathogenesis and vulnerability as well as therapeutic resistance. This computational tool holds promise in advancing our understanding of critical tumor biology, particularly in scenarios where only archival samples are available.

About Fierce Biotech

Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free here.

About Fierce Pharma

Biopharma is a fast-growing world where big ideas come along daily. Our readers rely on Fierce Pharma for the latest news, analysis and data on drugs and the companies that make them. Fierce Pharma covers the pharma waterfront, from late-stage drug development through the entire lifecycle— tracking regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation, M&A deals and beyond. Our aim is to analyze the day’s news, showing readers not only what they need to know, but why they need to know it. Beyond the daily, the Fierce Pharma team produces special reports that take stock of the industry’s products and finances, and shed new light on industry trends.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com